References
- Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol.50(7), E1–E157 (2007).
- Antman EM, Morrow DA, McCabe CH et al.; EXTRACT-TIMI 25 Investigators. enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Eng. J. Med.354, 1477–1488 (2006).
- Antman EM, Hand M, Armstrong PW et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol.51(2), 210–247 (2008).
- Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J.28(13), 1598–1660 (2007).
- Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet355(9219), 1936–1942 (2000).
- Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation114(8), 774–782 (2006).
- Fitchett DH, Borgundvaag B, Cantor W et al. Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm. Can. J. Cardiol.22(8), 663–677 (2006).
- Mahaffey KW, Cohen M, Garg J et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA294(20), 2594–2600 (2005).
- Mehta SR, Granger CB, Eikelboom JW et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J. Am. Coll. Cardiol.50(18), 1742–1751 (2007).
- Petersen JL, Mahaffey KW, Hasselblad V et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for anti-thrombin therapy in non-ST segment elevation acute coronary syndromes. JAMA292(1), 89–96 (2004).
- Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG. Predictors and 1-year outcome of major bleeding in patients with non-ST elevation acute coronary syndromes: Insights from the Canadian Acute Coronary Syndrome Registries. Am. Heart J.150, 690–694 (2005).
- The Synergy Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. Primary results of the SYNERGY randomized trial. JAMA292, 45–54 (2004).
- Yusuf S, Mehta SR, Chrolavicius S et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med.354(14), 1464–1476 (2006).
- Yusuf S, Mehta SR, Chrolavicius S et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA295(13), 1519–1530 (2006).